Recently, two MYC/BCL2 double-hit/HGBL DLBCL cell lines were shown to be sensitive to combination treatment of tigecycline, a mitochondrial translation inhibitor, plus doxycycline and venetoclax [74], but neither cell line was sensitive to tigecycline alone, which is consistent with our findings. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.